Please ensure Javascript is enabled for purposes of website accessibility

Why bluebird bio Inc, Juno Therapeutics Inc, and Alnylam Pharmaceuticals, Inc. Jumped Today

By Brian Orelli, PhD - Feb 16, 2016 at 4:02PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The trio of biotechs were in investors' good graces today.

What: On Tuesday, at 2:50 p.m. EST bluebird bio (BLUE -5.83%), Juno Therapeutics (JUNO), and Alnylam Pharmaceuticals (ALNY -2.93%) were up 10%, 7.6%, and 7.5% respectively. The only obvious connection between the three is that they're all biotechs without any products on the market -- none have any obvious news that justifies their moves. The broader NASDAQ Biotechnology Index is up Tuesday as well, albeit not as much as these lucky companies.

So what: Don't like the red that your development-stage biotech is experiencing? In this market, you just have to wait a few days, and there's a good chance that stock will have a big move in the other direction.

The moves on sentiment can be nauseous. And unfortunately there's been more down days than up days this year.

ALNY Chart


Now what: While the chart, might look like bluebird bio, Juno, and Alnylam have hit bottom, it's hard to know when this rollercoaster ride is going to end.

Assuming we're in for a few more gyrations up and down, investors have two choices: They can try to time the peaks and valleys with their buys and sells, or they can just ignore it and hold through the volatility. All three biotechs are scheduled to release clinical trial data this year, which should cause the companies' shares to trade on fundamentals rather than sentiment -- at least for a day or two.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Alnylam Pharmaceuticals, Inc. Stock Quote
Alnylam Pharmaceuticals, Inc.
$142.20 (-2.93%) $-4.29
bluebird bio, Inc. Stock Quote
bluebird bio, Inc.
$4.04 (-5.83%) $0.25
Juno Therapeutics, Inc. Stock Quote
Juno Therapeutics, Inc.

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.